Back to results
US 2014/0155430 A1Published application
Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
AssigneeEnVivo Pharmaceuticals, Inc.
InventorsRichard Chesworth, Gideon Shapiro, Gerhard Koenig
Life of this patent
Estimating the term…
Abstract
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.
Claims13
A method of treating negative symptoms associated with Schizophrenia in a patient in need thereof, comprising:
- administering to said patient a daily dose in the range of between 0.1 mg to 3.0 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.